Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Ivanidze J, Sharbatdaran A, McCalla A, Brandmaier A, Andreopoulou E, Cristofanilli M, Cigler T, Balogun OD, Magge RS, Liechty B, Karakatsanis NA, Nehmeh SA, Agee MA, Jean J, Osborne JR, Beal K, Schwartz TH, Pannullo SC, Knisely JPS, Ramakrishna R. [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases. Eur J Radiol. 2024 Dec; 181:111791.
-
Ping J, Jia G, Cai Q, Guo X, Tao R, Ambrosone C, Huo D, Ambs S, Barnard ME, Chen Y, Garcia-Closas M, Gu J, Hu JJ, John EM, Li CI, Nathanson K, Nemesure B, Olopade OI, Pal T, Press MF, Sanderson M, Sandler DP, Yoshimatsu T, Adejumo PO, Ahearn T, Brewster AM, Hennis AJM, Makumbi T, Ndom P, O'Brien KM, Olshan AF, Oluwasanu MM, Reid S, Yao S, Butler EN, Huang M, Ntekim A, Li B, Troester MA, Palmer JR, Haiman CA, Long J, Zheng W. Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.
-
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol. 2024 06 10; 42(17):2050-2060.
-
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar; 19(8):559-573.
-
Lee J, Kim H, Bae SJ, Ji JH, Lee JW, Son BH, Ahn SH, Jeong J, Lee SB, Ahn SG. Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Netw Open. 2022 11 01; 5(11):e2243935.
-
Chae SY, Park SH, Lee HS, Ahn JH, Kim SB, Jung KH, Kim JE, Ahn SH, Son BH, Lee JW, Ko BS, Kim HJ, Gong G, Oh JS, Park SY, Moon DH. Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Sci Rep. 2022 05 12; 12(1):7858.
-
Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, Tadros A. Can We Successfully De-Escalate Axillary Surgery in Women Aged = 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Ann Surg Oncol. 2022 Apr; 29(4):2263-2272.
-
Song IH, Kim YA, Heo SH, Bang WS, Park HS, Choi YH, Lee H, Seo JH, Cho Y, Jung SW, Kim HJ, Ahn SH, Lee HJ, Gong G. The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. Cancer Res Treat. 2022 Oct; 54(4):1111-1120.
-
Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV. Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). Int J Mol Sci. 2021 Aug 19; 22(16).
-
Ryu HH, Ahn SH, Kim SO, Kim JE, Kim JS, Ahn JH, Jung KH, Kim SB, Ko BS, Lee JW, Son BH, Shin HJ, Kim HH, Gong GY, Kim HJ. Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. Sci Rep. 2021 05 18; 11(1):10510.